Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for InMed Pharmaceuticals (INM) over the last 5 years, with Jun 2024 value amounting to -$9,293.

  • InMed Pharmaceuticals' Cash from Investing Activities rose 100.00% to -$2 in Q1 2024 from the same period last year, while for Mar 2024 it was -$887,263, marking a year-over-year decrease of 60.97%. This contributed to the annual value of -$9,293 for FY2024, which is 98.60% up from last year.
  • InMed Pharmaceuticals' Cash from Investing Activities amounted to -$9,293 in FY2024, which was up 98.60% from -$661,804 recorded in FY2023.
  • In the past 5 years, InMed Pharmaceuticals' Cash from Investing Activities registered a high of $3.8 million during FY2020, and its lowest value of -$672,999 during FY2022.
  • Over the past 3 years, InMed Pharmaceuticals' median Cash from Investing Activities value was -$661,804 (recorded in 2023), while the average stood at -$448,032.
  • Per our database at Business Quant, InMed Pharmaceuticals' Cash from Investing Activities plummeted by 38,914.43% in 2022 and then spiked by 98.60% in 2024.
  • InMed Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $3.8 million in 2020, then plummeted by 100.05% to -$1,725 in 2021, then crashed by 38,914.43% to -$672,999 in 2022, then increased by 1.66% to -$661,804 in 2023, then soared by 98.60% to -$9,293 in 2024.